Company Overview
Snapshot
Founded in January 2023 by Kashif Sadiq, DenovAI Biotech operates with 11–50 employees. The company has raised a total of $4 million across two funding rounds from six investors. In February 2024, DenovAI Biotech secured a Seed funding round.
Business overview
DenovAI Biotech develops foundational technology platforms that utilize AI to design proteins de novo, or completely from scratch. The company focuses on creating next-generation therapeutics such as high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters, all tailored to bind to specific targets. Its AI-based platform aims to accelerate the discovery process for high-affinity binders and broaden therapeutic applications across various diseases, serving the pharmaceuticals and biotechnology industries within the Health Tech & Life Sciences sector.
Strategic signal
In December 2023, DenovAI Biotech was highlighted for its AI-powered biophysics solution designed to accelerate and reduce the cost of antibody discovery. This development is significant for the pharmaceutical industry as it promises to enhance the identification of antibodies crucial for immune system defense, signaling a potential for faster and more efficient drug development processes.
Log in to access full profile ›Company Intelligence Q&A
- Who founded DenovAI Biotech?
- DenovAI Biotech was founded by Kashif Sadiq in January 2023.
- What is DenovAI Biotech's core technology?
- DenovAI Biotech's core technology is an AI-based platform that designs proteins de novo, enabling the creation of high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters tailored to specific targets.
- What was a key development for DenovAI Biotech in December 2023?
- In December 2023, DenovAI Biotech was recognized for its AI-powered biophysics solution, which aims to expedite and reduce the costs associated with antibody discovery for therapeutic use.
- Which organizations support DenovAI Biotech's initiatives?
- DenovAI Biotech is supported by organizations such as AION Labs, Pfizer, AstraZeneca, Merck, Teva, Amazon Web Services, the Israel Innovation Authority, and the Israel Biotech Fund.
- When did DenovAI Biotech receive its Seed funding?
- DenovAI Biotech secured a Seed funding round in February 2024 from Amiti Ventures.